

Moises Alberto Suarez-Zdunek¹, Alan Winston², Luxsena Sukumaran³, Nikolai S. Kirkby⁴, Susanne D. Nielsen^{1,5}, Caroline S. Sabin³

¹Viroimmunology Research Unit, Dept. of Infectious Diseases, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark; ²Dept. of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom; ³Institute of Global Health, Royal Free Campus, University College London, London, United Kingdom; ⁴Dept. of Clinical Microbiology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark; ⁵Dept. of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

BACKGROUND

Latent cytomegalovirus (CMV) infection has been linked to cardiovascular disease (CVD), possibly through chronic inflammation¹. However, the impact of CMV on traditional CVD risk factors is poorly understood². HIV is also associated with chronic inflammation and CVD, but it is unknown if HIV and CMV act synergistically to influence CVD risk.

AIMS

1. Determine if CMV IgG serostatus/concentrations are associated with traditional CVD risk factors
2. Determine if the associations are modified by HIV status.

METHODS

Study design: Cross-sectional study from the prospective POPPY Study in the UK and Ireland³.

Study population: Adult people with HIV aged ≥50 years and controls (people with HIV aged <50 and people without HIV aged ≥50 years).

Exposures: CMV IgG serostatus and concentrations measured on plasma at study entry (2013-2016).

Outcomes: *Estimated 10-year CVD risk:* SCORE2 based on age, sex, smoking, blood pressure and non-HDL concentrations. *Hypertension:* Blood pressure ≥140/90, use of antihypertensives and/or self-reported diagnosis. *LDL levels:* Measured in participants not using lipid-lowering drugs.

Statistics: (1) Logistic and linear regressions before and after progressive adjustment for a) HIV status b) age, sex, ethnicity c) smoking, body-mass index (BMI). (2) Interaction between CMV IgG and HIV status assessed in people aged ≥50.

Both in people with and without HIV, CMV IgG serostatus and concentrations are associated with higher estimated CVD risk and lower LDL levels, but this association may be explained by confounding from demographic factors.



RESULTS

A total of 1017 people with HIV and 294 people without HIV were included (Table 1).

- **Estimated CVD risk** (Fig. 1): Associations between CMV IgG serostatus and concentrations and SCORE2 were attenuated after adjustment for sex, age, and ethnicity.
- **Hypertension** (Fig. 2): No association with CMV IgG serostatus and concentrations.
- **LDL levels** (Fig. 2): Associations between CMV IgG serostatus and concentrations and lower LDL levels was attenuated after adjustment for sex, age, and ethnicity.
- **HIV/CMV:** No interaction between CMV IgG concentrations and HIV status found ($P_{int}=0.48$).

Fig. 1. Associations of CMV IgG serostatus/concentrations and SCORE2. β indicates differences in SCORE2 before and after progressive adjustments for 1) HIV status 2) age, sex, ethnicity 3) smoking and BMI. ^aPer doubling.

SCORE2	β (95% CI), P	CMV IgG concentrations ^a	β (95% CI), P
Positive CMV serostatus	0.34 (-0.32, 1.01), 0.31	Positive CMV serostatus	0.13 (0.03, 0.23), <0.01
+ HIV status	1.00 (0.28, 1.71), <0.01	+ HIV status	0.27 (0.16, 0.38), <0.001
+ age, sex, ethnicity	-0.14 (-0.60, 0.32), 0.56	+ age, sex, ethnicity	-0.02 (-0.09, 0.05), 0.53
+ smoking, BMI	-0.09 (-0.49, 0.31), 0.67	+ smoking, BMI	-0.03 (-0.09, 0.04), 0.40

Fig. 2. Associations of CMV IgG serostatus/concentrations, hypertension, and LDL levels among those not treated with lipid-lowering drugs. Estimates before and after progressive adjustment for 1) HIV status 2) age, sex, ethnicity 3) smoking, and BMI. ^aPer doubling.




TABLE 1 Participant characteristics (N = 1311)

Variables	People with HIV (N = 1017)	People without HIV (N = 294)
N (%) or median (IQR)		
Age, years	52 (47–59)	58 (53–63)
Male sex	870 (85%)	188 (64%)
White ethnicity	857 (84%)	263 (89%)
Current smoking	256 (25%)	39 (13%)
BMI (kg/m ²)	25.5 (23.2–28.2)	26.8 (24.2–29.5)
Positive CMV serostatus	990 (97%)	216 (73%)
Years on antiretrovirals	10.3 (5.2–16.7)	NA
Current CD4+ count/ μ L	630 (480–812)	NA
HIV RNA <50 copies/ μ L	920 (91%)	NA

CONCLUSIONS

CMV IgG serostatus and concentrations in people with and without HIV were not associated with higher estimated CVD risk, hypertension, and LDL levels after adjustment for sex, age, and ethnicity. This highlights the importance of demographic factors when interpreting the effect of CMV on CVD.

CONTACT INFORMATION



Moises Alberto Suarez-Zdunek, MD
msua0003@regionh.dk

REFERENCES

(1) Kawai K et al. J Am Heart Assoc 2025;14:e042670. (2) Nikolova KA et al. AIDS 2026;40:198-203. (3) Bagkeris et al. Int J Epidemiol 2018;47:1391-1392e.

ACKNOWLEDGEMENTS

POPPY Management Team: Saumitro Deb, Nicki Doyle, Paddy Mallon, Maxine Ng, Claire Petersen, Frank Post, Caroline Sabin, Memory Sachikonye, Alan Winston **POPPY Study Steering Committee:** Jasmini Alagaratnam, Jane Anderson, David Asboe, Marta Boffito, Fiona Burns, Aoife Cotter, Saumitro Deb, Nicki Doyle, Eoin Feeney, Paddy Mallon, Carlos Mejia, Maxine Ng, Claire Petersen, Frank Post, Caroline Sabin, Memory Sachikonye, Jaime Vera, Laura Waters, Alan Winston **POPPY Sites:** St Stephen's Centre, Chelsea and Westminster Hospital (Marta Boffito, Jasmini Alagaratnam, Ruth Byrne, Alexia Cheneau, Rosa Diaz Echeverria, Serge Fedele, Mohammed Hassan, Darwin Matila, Roya Movahedi, Beatrice Ouma, Javier Pinedo, Kathleen Ridor, Jad Salha, Sharom Scarpetta, Reda Yassein) Homerton Sexual Health Services, Homerton University Hospital (Jane Anderson, Tracey Fong, Lidia Ignatov, Jagrul Miah, Iain Reeves) Caldecot Centre, King's College Hospital (Frank Post, Birgit Barbini, Lucy Campbell, Luella Hanbury, Rachel Hung, Leigh McQueen, Zoe Ottaway, Daniel Trotman, Emily Wandolo) Mortimer Market Centre, Central and Northwest London NHS Foundation Trust (Laura Waters, Fowsiya Nur, Brittney Prusty, Sandra Coombes, Gosala Gopalakrishnan, Ebonoluwa Taiwo, Christos Karathanasis, Laura Hennelly, Claudia Benatar, Alejandro Arenas Pinto) Ian Charleson Day Centre, Royal Free Hospital (Fiona Burns, Tom Allan, Jonathan Edwards, Tom Fernandez, Jia Bo He, Katie Spears, Abigail Tobin) Clinical Research Facility, Royal Sussex County Hospital (Jaime Vera, Tanya Adams, Lisa Barbour, Kay Franklin, Chioma Iwuchukwu, Donards Tanedo, Andrea Terlingo, Vittorio Trevitt, Mikaela Vinick) Clinical Trials Centre, St. Mary's Hospital London (Alan Winston, Wilbert Ayap, Merle Henderson, Ishrat Jahan, Ian McGuinness, Idah Mojela, Marcelino Molina, Jacquie Ujetz) Catherine McAuley Centre, Mater Misericordiae University Hospital (Carlos Mejia Nijat Ahmadi, Alejandro Garcia, Binsa Jose) St Vincent's University Hospital (Eoin Feeney, Alejandro Garcia, Fiorina Rigonat, Stefano Savinelli) **POPPY methodology/statistics:** Caroline Sabin, Saumitro Deb, Hajra Okhai, Luxsena Sukumaran **Funders:** We acknowledge the use of the National Institute for Health Research (NIHR)/Wellcome Trust Clinical Research Facility at King's College Hospital. The research is also funded by the National Institute for Health Research Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. Supported in part by research grants from Investigator-Initiated Studies Program of Merck Sharp & Dohme LLC, ViV Healthcare and Gilead Sciences. The CMV IgG measurements were supported by Ketty & Ejvind Lyngsbæk's Foundation.

PLAIN LANGUAGE SUMMARY

Antibody levels against cytomegalovirus (CMV) were linked to higher estimated heart disease risk and lower cholesterol. However, these links were largely explained by differences in age, sex, and ethnicity. This shows that demographics matter when trying to understand if CMV infection increases heart disease risk.